Skip to content

Study · Animal study (in vivo) · mouse · 2008

4 results

A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease.

Matsuoka Y, Jouroukhin Y, Gray AJ, Ma L, Hirata-Fukae C, Li HF, Feng L, Lecanu L, Walker BR, Planel E, Arancio O, Gozes I, Aisen PS

The Journal of pharmacology and experimental therapeutics16 Jan 2008Cited by 169 (Europe PMC)

PMID18199809 (opens in a new tab)DOI10.1124/jpet.107.130526 (opens in a new tab)PepBankPUB-18199809
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In transgenic mice with early-to-moderate tauopathy, NAP reduced hyperphosphorylated soluble tau after three months.

    In plain wordsIn mice with tau pathology, NAP reduced soluble hyperphosphorylated tau after three months.

    Peptide
    Davunetide
    Outcome
    DecreaseHyperphosphorylated soluble tau
    Study

    Mousen: not reported in source

    Transgenic Alzheimer's disease-relevant tau pathology
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · Three monthsAs given in this study (Mouse).

    Source sentences

    Summary
    Three months of treatment with NAP at an early-to-moderate stage of tauopathy reduced the levels of hyperphosphorylated soluble and insoluble tau.
    1 context sentence
    Summary · context
    To assess whether an agent that modulates microtubule function can inhibit the pathogenic process and prevent cognitive deficits in a transgenic mouse model with AD-relevant tau pathology, we administered the neuronal tubulin-preferring agent, NAPVSIPQ (NAP).
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In transgenic mice with early-to-moderate tauopathy, NAP reduced hyperphosphorylated insoluble tau after three months.

    In plain wordsIn mice with tau pathology, NAP reduced insoluble hyperphosphorylated tau after three months.

    Peptide
    Davunetide
    Outcome
    DecreaseHyperphosphorylated insoluble tau
    Study

    Mousen: not reported in source

    Transgenic Alzheimer's disease-relevant tau pathology
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · Three monthsAs given in this study (Mouse).

    Source sentences

    Summary
    Three months of treatment with NAP at an early-to-moderate stage of tauopathy reduced the levels of hyperphosphorylated soluble and insoluble tau.
    1 context sentence
    Summary · context
    To assess whether an agent that modulates microtubule function can inhibit the pathogenic process and prevent cognitive deficits in a transgenic mouse model with AD-relevant tau pathology, we administered the neuronal tubulin-preferring agent, NAPVSIPQ (NAP).
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In transgenic mice with tau pathology, a 6-month NAP treatment course improved cognitive function.

    In plain wordsIn mice with tau pathology, NAP improved cognitive function after 6 months.

    Peptide
    Davunetide
    Outcome
    IncreaseCognitive function
    Study

    Mousen: not reported in source

    Transgenic Alzheimer's disease-relevant tau pathology
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated · 6 monthsAs given in this study (Mouse).

    Source sentences

    Summary
    A 6-month course of treatment improved cognitive function.
    1 context sentence
    Summary · context
    To assess whether an agent that modulates microtubule function can inhibit the pathogenic process and prevent cognitive deficits in a transgenic mouse model with AD-relevant tau pathology, we administered the neuronal tubulin-preferring agent, NAPVSIPQ (NAP).
  4. 04AnimalAnimal study (in vivo)Safety outcome

    In transgenic mice, no adverse effects were found after 6 months of NAP exposure.

    In plain wordsIn mice, researchers found no adverse effects after 6 months of NAP exposure.

    Peptide
    Davunetide
    Outcome
    Not applicableAdverse effects
    Study

    Mousen: not reported in source

    Transgenic Alzheimer's disease-relevant tau pathology
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · 6 monthsAs given in this study (Mouse).

    Source sentences

    Summary
    no adverse effects were found after 6 months of exposure to NAP.
    1 context sentence
    Summary · context
    To assess whether an agent that modulates microtubule function can inhibit the pathogenic process and prevent cognitive deficits in a transgenic mouse model with AD-relevant tau pathology, we administered the neuronal tubulin-preferring agent, NAPVSIPQ (NAP).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 1NCT01056965

Davunetide (AL-108) in Predicted Tauopathies - Pilot Study

University of California, San Franciscon = 12Jan 2010 to Dec 2012

Predicted Tauopathies, Including · Progressive Supranuclear Palsy · Frontotemporal Dementia With Parkinsonism Linked to Chromosome 17 · Corticobasal Degeneration Syndrome · Progressive Nonfluent Aphasia

Trial pageClinicalTrials.govUpdated 5 Apr 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.